Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

Julie E. Bauman; Nabil F. Saba; Denise J. Roe; Jessica R. Bauman; John M. Kaczmar; Aarti Bhatia; Jameel Muzaffar; Ricklie Julian; Steven Wang; Shethal Bearelly; Audrey Z. Baker; Conor Steuer; Anshu Giri; Barbara Burtness; Sara Centuori; Carlos Caulı́n; Robert J. Klein; Kathylynn Saboda; Stefanie Obara; Christine H. Chung

doi:10.1200/jco.22.01994

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC merits consideration as a selection criterion.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bauman et al. (2023) studied this question.

synapsesocial.com/papers/69d98e525e5bcb4e3b837030 https://doi.org/10.1200/jco.22.01994

View Full Paper

Ask AI

Bookmark

Share

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading